Skip to main content
. 2017 Mar 2;3(6):793–800. doi: 10.1001/jamaoncol.2016.6120

Figure 3. Recurrence-Free Survival in Biological Subgroups.

Figure 3.

Recurrence-free survival in 4 biological subgroups defined by cancer steroid hormone receptors and HER2 status (human epidermal growth factor receptor 2). ER indicates estrogen receptor; HR, hazard ratio; PR, progesterone receptor; T+CEF, 3 cycles of docetaxel followed by 3 cycles of cyclophosphamide, epirubicin, and fluorouracil; TX-CEX, 3 cycles of docetaxel plus capecitabine followed by 3 cycles of cyclophosphamide, epirubicin, and capecitabine.